Linked Life Data

16006588

Source:http://linkedlifedata.com/resource/pubmed/id/16006588

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-7-11
pubmed:abstractText
Recent evidence suggests that the progression of renal fibrosis is a reversible process, at least in experimental models. The present review summarizes the new insights concerning the mechanisms of progression and regression of renal disease and examines this novel evidence under the light of feasibility and transfer to human nephropathies. The involved mechanisms are discussed with particular emphasis on the fibrotic role of vasoactive peptides such as angiotensin II and endothelin and growth factors such as transforming growth factor (TGF)-beta. The possibility of regression is introduced by presenting the in vivo efficiency of antihypertensive treatments and of systems that antagonize the fibrogenic action of TGF-beta such as bone morphogenic protein-7 and HGF. Finally, we provide a brief description of the promising future directions and clinical considerations about the applications of the experimental data to humans.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1931-857X
pubmed:author
pubmed:issnType
Print
pubmed:volume
289
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
F227-34
pubmed:dateRevised
2011-4-28
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?
pubmed:affiliation
Institut National de la Santé et de la Recherche Médicale Unité 702, Hôpital Tenon, Paris, France. christos.chatziantoniou@tnn.ap-hop-paris.fr
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't